- Conditions
- Healthy
- Interventions
- CNTO 328 (Sp2/0-derived), CNTO 328 (CHO-derived), Placebo
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Lincoln, Nebraska • Neptune City, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1537–1560
of 4,633
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Osteoarthritis
- Interventions
- sodium hyaluronate, placebo
- Device
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- Myotonic Dystrophy Type 1 (DM1)
- Interventions
- VX-670, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- San Carlos, California • Gainesville, Florida • Fairway, Kansas + 5 more
- Conditions
- Obesity, Overweight
- Interventions
- Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 12
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Walnut Creek, California + 9 more
- Conditions
- Postherpetic Neuralgia
- Interventions
- Placebo, LX9211
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 22
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Greenbrae, California + 17 more
- Conditions
- Hyperlipidemia
- Interventions
- Atorvastatin, Placebo to Atorvastatin, Placebo to Ezetimibe, Ezetimibe, Placebo to Evolocumab, Evolocumab
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 18
- States / cities
- Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 15 more
- Conditions
- Fibromyalgia
- Interventions
- Sodium Oxybate, Sodium Oxybate & 6 Tablets, Sodium Oxybate & 8 Tablets, Sodium Oxybate Oral Solution (6 grams)
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Anaheim, California • Fair Oaks, California + 26 more
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Etoposide, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 503 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 22
- States / cities
- Fort Myers, Florida • Orlando, Florida • St. Petersburg, Florida + 18 more
- Conditions
- Sleep
- Interventions
- Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg, Naproxen Sodium 440 mg (BAYH6689), Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg, Naproxen Sodium 220 mg (BAYH6689), DPH 50mg, Ibuprofen 400 mg / Diphenhydramine citrate 76 mg
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 16 Years to 45 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Respiratory Syncytial Viruses, Lower Respiratory Tract Disease
- Interventions
- Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF, Placebo
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 25,236 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 156
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 126 more
- Conditions
- Participants Less Than 12 Months of Age With RSV Illness
- Interventions
- Motavizumab, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 0 Months to 12 Months
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 31
- States / cities
- Tucson, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 24 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Indacaterol 300 μg, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Torrance, California • Lebanon, New Hampshire
- Conditions
- Respiratory Distress Syndrome, Adult
- Interventions
- Human Mesenchymal Stromal Cells, Cell Reconstitution Media
- Biological
- Lead sponsor
- Michael A. Matthay
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 7
- States / cities
- Sacramento, California • San Francisco, California • Portland, Oregon + 3 more
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
- Interventions
- Cohort C: bevacizumab, Cohort C: placebo
- Drug
- Lead sponsor
- PPD Development, LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more
- Conditions
- Schizophrenia
- Interventions
- Placebo, RO5545965, risperidone
- Other · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
- Interventions
- TVB-2640 25 mg (US), TVB-2640 50 mg (US), Placebo (US), TVB-2640 50 mg (China), Placebo (China), TVB-2640 75 mg (US)
- Drug
- Lead sponsor
- Sagimet Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 12
- States / cities
- Chula Vista, California • Montclair, California • Sacramento, California + 9 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- QVA149, QAB149, NVA237, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,042 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Mesa, Arizona + 60 more
- Conditions
- Healthy Volunteers
- Interventions
- Risankizumab, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Drug Toxicity
- Interventions
- HPN-100, HPN-100 or Placebo, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Lung Transplant
- Interventions
- Tocilizumab, Placebo for Tocilizumab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more
- Conditions
- Obesity
- Interventions
- beta3-adrenergic receptor agonist
- Drug
- Lead sponsor
- Aaron Cypess
- Other
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Respiratory Distress Syndrome, Adult
- Interventions
- Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells, Plasma-Lyte A
- Biological
- Lead sponsor
- Michael A. Matthay
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 6
- States / cities
- San Francisco, California • Stanford, California • Boston, Massachusetts + 3 more
- Conditions
- Cancer, Chemotherapy-Induced Nausea and Vomiting, Nausea and Vomiting, Solid Tumor Cancer
- Interventions
- Dexamethasone, IV casopitant (placebo), IV casopitant (active), Ondansetron
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Robbinsdale, Minnesota
- Conditions
- Healthy
- Interventions
- Ad26.Mos4.HIV, Clade C gp140 plus adjuvant, Clade C gp140/Mosaic gp140 plus adjuvant, Placebo, gp140 HIV Bivalent Vaccine
- Biological · Other
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more